Skip to main content
OpenTrials
Completed

NCT Number: NCT04376008

A Prospective Study Of Free-Hand Transperineal Image Fusion Targeted Biopsies Under Local Anesthesia

This trial aims to prospectively assess the feasibility, complications and functional results of free-hand transperineal image fusion targeted biopsies under local anesthesia in a large group of patients.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Nanjing, Jiangsu, 210000, China

About this study

12-core transrectal ultrasound (TRUS) biopsy is one of the most performed urological procedures and remains the standard method for prostate cancer (PCa) histological diagnosis according to the most recent Guidelines. During the last decade, the transperineal prostate biopsy has attracted renewed interest. However, only a few studies and no large prospective studies investigated complications of the transperineal approaches.

Image fusion of Multi-parameter MRI (mpMRI) and TRUS guided prostate targeted biopsy had equivalent results with standard 12-core biopsy. Combination of targeted and standard biopsy was recommended in recent Guidelines. Image fusion targeted biopsy needs satisfactory anesthetic effect, and no prospective studies investigated feasibility in this approach under local anesthesia.

The scientific urological community is focusing on detection rate and concordance with final pathology of the radical prostatectomy specimen, which remain the cornerstones to assess the accuracy of a prostate biopsy technique. In this study, the investigators will additionally assess the functional results of erectile function and urinary function.

Together, the investigators will perform free-hand image fusion targeted biopsies plus standard biopsies under local anesthesia in patients recruited in this study. Then, Feasibility, such as peri-procedural pain, changes in patients quality of life; complications, such as infection rate and bleeding rate; functional results, such as erectile function and urinary function; and concordance with final pathology will be evaluated.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men more than 18 years old with clinical suspicion of prostate cancer;
  • Serum PSA ≤ 20 ng/ml within the previous 3 months;
  • Suspected stage ≤ T2 on rectal examination (organ-confined prostate cancer) within the previous 3 months;
  • No evidence of PSA increase by noncancerous factors, such as catheterization, bladder stones, or urinary tract infection including bacterial prostatitis;
  • Able to provide written informed consent.

Exclusion criteria

  • Prior prostate biopsy or prostate surgery;
  • Prior treatment for prostate cancer;
  • Contraindication to MRI (e.g. claustrophobia, pacemaker, estimated glomerular filtration rate ≤ 50mls/min);
  • Contraindication to prostate biopsy.

Treatment and study plan

Standard prostate biopsy

Procedure

Transperineal TRUS guided standard prostate biopsy (SB).

Targeted and standard prostate biopsy

Procedure

Transperineal Image fusion-guided targeted and standard prostate biopsy (TB+SB).

Primary outcomes

  1. Biopsy unfinished rates

    Time frame: 1 days

    The proportion of patients who failed to complete the biopsy due to various reasons during the biopsy

  2. Pain score

    Time frame: 3 days peri-biopsy

    Numerical pain scale score during biopsy, the minimum to maximum value is 0 to 10, and higher scores mean a worse outcome

  3. Hospitalization rate due to biopsy

    Time frame: 7 days post biopsy

    The proportion of subjects requiring hospitalization for various reasons within 7 days after puncture

Secondary outcomes

  1. Detection rates of clinically significant PCa

    Time frame: 30 days post biopsy

    Clinically significant prostate cancer is considered as: biopsy Gleason score ≥3+4 or maximum cancer core length ≥5 mm.

  2. Detection rates of PCa

    Time frame: 30 days post biopsy

    Prostate cancer is considered as: biopsy Gleason score ≥3+3

  3. Biopsy-related complication rates

    Time frame: 30 days post biopsy

  4. Biopsy time

    Time frame: 1 days

    How much time is used during biopsy

  5. Consistency rate with final pathology

    Time frame: 30 days post biopsy

    Concordance rate between biopsy and final pathology

  6. international index of erectile function-5 (IIEF-5) score

    Time frame: 30 days post biopsy

    pre- and post-procedural erectile function score, the minimum to maximum value is 0 to 25, and higher scores mean a better outcome

  7. International prostate symptom score (IPSS)

    Time frame: 30 days post biopsy

    pre- and post-procedural urinary function score, the minimum to maximum value is 0 to 35, and higher scores mean a worse outcome

Sponsors and collaborators

Lead sponsor

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Other

Registry information

Official study title

Evaluation of Feasibility, Complications And Functional Results Of Free-Hand Transperineal Image Fusion Targeted Biopsies Under Local Anesthesia: A Prospective Study

Important dates

Study start
2018
Primary completion
2021
Study completion
2022
First posted
May 6, 2020
Registry last updated
Oct 24, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.